Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus Disease in High-Risk Kidney Transplant Recipients
JAMA Author Interviews · American Medical Association
July 3, 202317m 57s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Valganciclovir is standard cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant recipients, but its use is limited by myelosuppression. JAMA Deputy Editor Preeti Malani, MD, MSJ, interviews Ajit Limaye, MD, from the University of Washington, about a multinational randomized trial of letermovir vs valganciclovir for CMV prevention in CMV-negative patients receiving a kidney from a CMV-positive donor. Related Content: